Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies

被引:0
作者
Raffaele Frazzi
Charles Auffray
Angela Ferrari
Perla Filippini
Sergio Rutella
Alfredo Cesario
机构
[1] IRCCS “Arcispedale S. Maria Nuova”,Laboratory of Translational Research
[2] European Institute for Systems Biology and Medicine (EISBM),Division of Hematology
[3] IRCCS “Arcispedale S. Maria Nuova”,Division of Translational Medicine
[4] Sidra Medical and Research Centre,Clinical Governance and International Research Activities
[5] John van Geest Cancer Research Centre,Division of Thoracic Surgery
[6] College of Science and Technology,undefined
[7] Nottingham Trent University,undefined
[8] Fondazione Policlinico Gemelli,undefined
[9] Università Cattolica del Sacro Cuore,undefined
[10] European Association of Systems Medicine,undefined
来源
Journal of Translational Medicine | / 14卷
关键词
Systems medicine; Lymphoproliferative disorder; Massively-Parallel sequencing; High throughput RNA sequencing;
D O I
暂无
中图分类号
学科分类号
摘要
Although survival rates for lymphoproliferative disorders are steadily increasing both in the US and in Europe, there is need for optimizing front-line therapies and developing more effective salvage strategies. Recent advances in molecular genetics have highlighted the biological diversity of lymphoproliferative disorders. In particular, integrative approaches including whole genome sequencing, whole exome sequencing, and transcriptome or RNA sequencing have been instrumental to the identification of molecular targets for treatment. Herein, we will discuss how genomic, epigenomic and proteomic approaches in lymphoproliferative disorders have supported the discovery of molecular lesions and their therapeutic targeting in the clinic.
引用
收藏
相关论文
共 560 条
[1]  
Cesario A(2014)P4 medicine needs P4 education Curr Pharm Des 20 6071-6072
[2]  
Auffray C(2014)A systems medicine clinical platform for understanding and managing non-communicable diseases Curr Pharm Des 20 5945-5956
[3]  
Russo P(2014)Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study Lancet Oncol 15 931-942
[4]  
Hood L(2013)Mechanisms of programmed DNA lesions and genomic instability in the immune system Cell 152 417-429
[5]  
Cesario A(2014)Racial differences in three major NHL subtypes: descriptive epidemiology Cancer Epidemiol 39 8-13
[6]  
Auffray C(2011)The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 117 5019-5032
[7]  
Agusti A(2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105-116
[8]  
Apolone G(2006)CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379-391
[9]  
Balling R(2015)B-cell receptor signaling in diffuse large B-cell lymphoma Semin Hematol 52 77-85
[10]  
Barbanti P(2008)Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci USA 105 13520-13525